Short answer · Medically reviewed summary · Last updated: 2026-04-07
High Myopia, typically defined as a refractive error of -6.00 diopters or greater or an axial length of 26.5 mm or more, is managed primarily through refractive correction, lifestyle adjustments, and monitoring for sight-threatening complications. While there is no cure to reverse the anatomical changes of High Myopia, current treatments focus on optimizing visual acuity and reducing the risk of associated pathologies like retinal detachment and myopic maculopathy. What are the primary treatments for High Myopia? The management of High Myopia is highly personalized based on the patient's age, the severity of the refractive error, and the presence of underlying retinal changes.
High Myopia, typically defined as a refractive error of -6.00 diopters or greater or an axial length of 26.5 mm or more, is managed primarily through refractive correction, lifestyle adjustments, and monitoring for sight-threatening complications. While there is no cure to reverse the anatomical changes of High Myopia, current treatments focus on optimizing visual acuity and reducing the risk of associated pathologies like retinal detachment and myopic maculopathy.
The management of High Myopia is highly personalized based on the patient's age, the severity of the refractive error, and the presence of underlying retinal changes. First-line treatment involves standard corrective lenses (spectacles or contact lenses) to achieve clear vision. For many patients with High Myopia, rigid gas-permeable or scleral contact lenses are preferred over soft lenses because they provide superior visual quality for high refractive errors and can help manage corneal astigmatism often associated with the condition.
While pharmacological interventions for High Myopia are primarily used for myopia control in children rather than reversing the condition in adults, low-dose atropine (various formulations) is the most studied agent for slowing axial elongation. For adults, non-pharmacological interventions are crucial for maintaining eye health. These include:
Current clinical research for High Myopia is focused on halting the progression of axial elongation. Notable areas of investigation include the use of peripheral defocus management through specialized spectacle lenses and orthokeratology. Emerging treatments also explore the use of cross-linking therapies to strengthen the scleral tissue, aiming to prevent the pathological stretching that characterizes severe cases. Patients are encouraged to consult clinical trial registries to see if they meet the criteria for studies investigating novel scleral-strengthening interventions.
Because High Myopia can affect the entire structure of the eye, a multidisciplinary approach is vital. Your care team should ideally include:
Medical Disclaimer: This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment; always consult with a qualified healthcare professional regarding your specific medical condition and treatment plan.